exalenz bioscience
exalenz bioscience ltd develops and commercializes systems that extract vital information for diagnostics from subtle changes in patients’ exhaled breath using the company’s breathid technology platform .
exalenz bioscience ltd. develops and commercializes advanced systems that extract vital information for diagnostics from subtle changes in the patient' s exhaled breath based on its breathid technology platform. these products improve the quality of patient care, enhance clinic and medical center efficiencies and fuel revenue generation. their proprietary core technology enables medical specialists to identify and manage specific digestive and liver conditions with unprecedented ease, patient comfort, and clinical precision .
exalenz’ mission is to become a leading provider of accurate, breath test - based, point - of - care disease management solutions for a broad range of gi and liver disorders .
the design of sophisticated diagnostic systems that are simple to operate is a hallmark of exalenz. the company conducts ongoing research in collaboration with leading clinical and industrial partners in the u. s. , europe, asia, and israel .
note: javascript is disabled or is not supported by your browser. for this reason, some items on this page will be unavailable. for more information about this message, please visit this page: about urltoken .
helicobacter pylori is a small, curved, microaerophilic, gram - negative, rod - shaped bacterium .
about two - thirds of the world’s population is infected, but it is more common in developing countries .
usually asymptomatic, but h. pylori is the major cause of peptic ulcer disease and gastritis worldwide, which present as gnawing or burning epigastric pain. less commonly, symptoms include nausea, vomiting, or loss of appetite. infected people have a 2 - to 6 - fold increased risk of developing gastric cancer and mucosal - associated - lymphoid - type (malt) lymphoma compared with their uninfected counterparts .
fecal antigen assay, urea breath test, rapid urease test, or histology of biopsy specimen. a positive serology indicates present or past infection .
asymptomatic infections do not need to be treated. patients with active duodenal or gastric ulcers should be treated if they are infected. treatment should be determined on an individual basis. standard treatments are clarithromycin triple therapy (proton pump inhibitor [ ppi ] + clarithromycin + amoxicillin or metronidazole) or bismuth quadruple therapy (ppi or h2 - blocker + bismuth + metronidazole + tetracycline). see urltoken .
chey wd, wong bc. american college of gastroenterology guideline on the management of helicobacter pylori infection. am j gastroenterol. 2007 aug; 102 (8): 1808–25 .
lindkvist p, wadstrom t, giesecke j. helicobacter pylori infection and foreign travel. j infect dis. 1995 oct; 172 (4): 1135–6 .
peterson wl, fendrick am, cave dr, peura da, garabedian - ruffalo sm, laine l. helicobacter pylori - related disease: guidelines for testing and treatment. arch intern med. 2000 may 8; 160 (9): 1285–91 .
united states aruba afghanistan angola anguilla åland islands albania andorra united arab emirates argentina armenia american samoa antarctica french southern territories antigua and barbuda australia austria azerbaijan burundi belgium benin bonaire, sint eustatius and saba burkina faso bangladesh bulgaria bahrain bahamas bosnia and herzegovina saint barthélemy belarus belize bermuda bolivia, plurinational state of brazil barbados brunei darussalam bhutan bouvet island botswana central african republic canada cocos (keeling) islands switzerland chile china côte d' ivoire cameroon congo, the democratic republic of the congo cook islands colombia comoros cape verde costa rica cuba curaçao christmas island cayman islands cyprus czech republic germany djibouti dominica denmark dominican republic algeria ecuador egypt eritrea western sahara spain estonia ethiopia finland fiji falkland islands (malvinas) france faroe islands micronesia, federated states of gabon united kingdom georgia guernsey ghana gibraltar guinea guadeloupe gambia guinea - bissau equatorial guinea greece grenada greenland guatemala french guiana guam guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia isle of man india british indian ocean territory ireland iran, islamic republic of iraq iceland israel italy jamaica jersey jordan japan kazakhstan kenya kyrgyzstan cambodia kiribati saint kitts and nevis korea, republic of kuwait lao people' s democratic republic lebanon liberia libya saint lucia liechtenstein sri lanka lesotho lithuania luxembourg latvia macao saint martin (french part) morocco monaco moldova, republic of madagascar maldives mexico marshall islands macedonia, the former yugoslav republic of mali malta myanmar montenegro mongolia northern mariana islands mozambique mauritania montserrat martinique mauritius malawi malaysia mayotte namibia new caledonia niger norfolk island nigeria nicaragua niue netherlands norway nepal nauru new zealand oman pakistan panama pitcairn peru philippines palau papua new guinea poland puerto rico korea, democratic people' s republic of portugal paraguay palestine, state of french polynesia qatar réunion romania russian federation rwanda saudi arabia sudan senegal singapore south georgia and the south sandwich islands saint helena, ascension and tristan da cunha svalbard and jan mayen solomon islands sierra leone el salvador san marino somalia saint pierre and miquelon serbia south sudan sao tome and principe suriname slovakia slovenia sweden swaziland sint maarten (dutch part) seychelles syrian arab republic turks and caicos islands chad togo thailand tajikistan tokelau turkmenistan timor - leste tonga trinidad and tobago tunisia turkey tuvalu taiwan, province of china tanzania, united republic of uganda ukraine united states minor outlying islands uruguay united states uzbekistan holy see (vatican city state) saint vincent and the grenadines venezuela, bolivarian republic of virgin islands, british virgin islands, u. s. viet nam vanuatu wallis and futuna samoa yemen south africa zambia zimbabwe
disclaimer: in the us, the breathid ® hp system and the breathid ® hp lab system are intended for use in the qualitative detection of h. pylori. they have fda 510 (k) clearance and an approved nda for the 13 c - urea tablet and citrica powder. other applications are limited in the us by federal law to investigational use only. in europe, breathid ® devices have ce approval for diagnostic monitoring of the digestive system and liver. in china and additional countries, the breathid ® hp device is approved for the detection of h. pylori
for inquiries related to this message please contact support. for sales inquiries, please visit urltoken
if you believe this to be in error, please confirm below that you are not a robot by clicking
i' m not a robot
below .
please make sure your browser supports javascript and cookies and that you are not blocking them from loading. for more information you can review the terms of service and cookie policy .
the h. pylori breath test is a simple and safe test used to detect an active h. pylori infection
if left untreated, h. pylori bacteria can cause gastritis (an inflammation or irritation of the stomach lining) and duodenal or gastric ulcers
the breathid technology platform answers the long - standing need for fast, convenient and accurate assessment and monitoring of functional diseases of the liver and gastrointestinal tract. it measures parts - per - million changes in the molecular 13c / 12c ratio of the patient' s exhaled breath - continuously, automatically and in real time. breathid products are designed for mobility and user - friendly operation, and can be performed in the office or clinic .
the company’s flagship breath id hp is an extremely accurate, easy - to - use, self - calibrating urea breath test (ubt) and the emerging gold standard to diagnose, monitor and manage gastric h. pylori bacteria infection. it is estimated that two - thirds of the world' s population is infected with h. pylori. recent studies estimate that more than 90% of duodenal ulcers and 80% of gastric complications are caused by h. pylori, conditions which have been to ultimately lead to stomach cancer and other gastric complications if left untreated .
as their name implies, they define
excellence
as successfully meeting patient and practitioner needs. their technology furthers this goal by providing both medical professionals and patients with advanced solutions and vital diagnostic information .
sign up for a free crunchbase account to follow and track organizations you care about .
terms of service | privacy policy | © 2018 crunchbase inc. all rights reserved .
descriptive keyword for an organization (e. g. saas, android, cloud computing, medical device )
this field describes an organization' s most recent funding status (e. g. early stage venture, late stage venture, m & a )
the company’s proprietary core technology enables medical specialists to easily identify and manage specific digestive and liver conditions while ensuring both clinical precision and patient comfort. the breathid hp is a clinically proven, easy, and accurate single - step urea breath test for diagnosing and monitoring h. pylori infection in adults .
the page you are searching for does not exist. either it has moved, or the link is broken .
copyright © 2018 pr newswire association llc. all rights reserved. a cision company.
exalenz bioscience ltd. is a biotechnology company that develops and manufactures non-invasive diagnostic medical devices for gastrointestinal and liver conditions . the company ’s technology uses a continuous flow of a patient ’s breath to diagnose illness . exalenz is headquartered in modi’in , israel and is publicly traded on the tel aviv stock exchange as exen . u.s. headquarters are in jersey city , new jersey . exalenz ’s devices use real time breath gas analysis to detect the ratio between different carbon dioxide isotopes - ¹³ co ₂ and ¹² co ₂ . the detection technology is termed molecular correlation spectroscopy ( mcs ) . laser-like light sources emit infrared beams in the absorption spectrum for co ₂ only . this absorption is measured . mcs is extremely sensitive and can work with smaller sample cells and a lower breath flow rate than other breath methods . minute differences in the gas ratio indicate the presence of certain gastric or liver diseases , including gastroparesis , liver failure , fatty liver and liver cancer . exalenz ’s breathid , a first generation device , received an eu ce mark on march 18 , 2002 , and the u.s. food and drug administration ( fda ) on july 9 , 2001 . a second generation product , breathid hp breath test system , received an eu ce mark on april 18 , 2013 and fda clearance on may 22 , 2013 . the breathid hp breath test system is used to perform a diagnostic test for the presence of helicobacter pylori , a bacterium that can cause peptic ulcers and is associated with gastric cancer . h.pylori is a very common bacterium , reported to be present in up to two-thirds of the world population . blood or stool tests are also used to diagnose h. pylori . it takes days to get results from either test . the breathid hp test takes 10 – 15 minutes . physicians receive results at the end of the test . 
exalenz bioscience ltd. is a biotechnology company that develops and manufactures non-invasive diagnostic medical devices for gastrointestinal and liver conditions. the company ’s technology uses a continuous flow of a patient ’s breath to diagnose illness. exalenz is headquartered in modi’in, israel and is publicly traded on the tel aviv stock exchange as exen. u.s. headquarters are in jersey city, new jersey. exalenz ’s devices use real time breath gas analysis to detect the ratio between different carbon dioxide isotopes - ¹³ co ₂ and ¹² co ₂. the detection technology is termed molecular correlation spectroscopy (mcs). laser-like light sources emit infrared beams in the absorption spectrum for co ₂ only. this absorption is measured. mcs is extremely sensitive and can work with smaller sample cells and a lower breath flow rate than other breath methods. minute differences in the gas ratio indicate the presence of certain gastric or liver diseases, including gastroparesis, liver failure, fatty liver and liver cancer. exalenz ’s breathid, a first generation device, received an eu ce mark on march 18, 2002, and the u.s. food and drug administration (fda) on july 9, 2001. a second generation product, breathid hp breath test system, received an eu ce mark on april 18, 2013 and fda clearance on may 22, 2013. the breathid hp breath test system is used to perform a diagnostic test for the presence of helicobacter pylori, a bacterium that can cause peptic ulcers and is associated with gastric cancer. h.pylori is a very common bacterium, reported to be present in up to two-thirds of the world population. blood or stool tests are also used to diagnose h. pylori. it takes days to get results from either test. the breathid hp test takes 10 – 15 minutes. physicians receive results at the end of the test.
exalenz bioscience ltd. is a biotechnology company that develops and manufactures non-invasive diagnostic medical devices for gastrointestinal and liver conditions. the company ’s technology uses a continuous flow of a patient ’s breath to diagnose illness. exalenz is headquartered in modi’in, israel and is publicly traded on the tel aviv stock exchange as exen. u.s. headquarters are in jersey city, new jersey. exalenz ’s devices use real time breath gas analysis to detect the ratio between different carbon dioxide isotopes - ¹³ co ₂ and ¹² co ₂. the detection technology is termed molecular correlation spectroscopy (mcs). laser-like light sources emit infrared beams in the absorption spectrum for co ₂ only. this absorption is measured. mcs is extremely sensitive and can work with smaller sample cells and a lower breath flow rate than other breath methods. minute differences in the gas ratio indicate the presence of certain gastric or liver diseases, including gastroparesis, liver failure, fatty liver and liver cancer. exalenz ’s breathid, a first generation device, received an eu ce mark on march 18, 2002, and the u.s. food and drug administration (fda) on july 9, 2001. a second generation product, breathid hp breath test system, received an eu ce mark on april 18, 2013 and fda clearance on may 22, 2013. the breathid hp breath test system is used to perform a diagnostic test for the presence of helicobacter pylori, a bacterium that can cause peptic ulcers and is associated with gastric cancer. h.pylori is a very common bacterium, reported to be present in up to two-thirds of the world population. blood or stool tests are also used to diagnose h. pylori. it takes days to get results from either test. the breathid hp test takes 10 – 15 minutes. physicians receive results at the end of the test.